Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination With mFOLFOX6 or FOLFIRI in Patients With Solid Tumors

NCT07498725 is registered in ClinicalTrials.gov with LARKSPUR BIOSCIENCES, INC. as lead sponsor.

NCT NCT07498725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07498725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination With mFOLFOX6 or FOLFIRI in Patients With Solid Tumors
Lead sponsor
LARKSPUR BIOSCIENCES, INC.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 7, 2026
Completion date
June 30, 2029
Enrollment
120 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms